Treatment with azathioprine and cyclic methylprednisolone has little or no effect on bioactivity in anti-interferon beta antibody-positive patients with multiple sclerosis.
Bojar
M
M
Zajac
M
M
Meluzínová
E
E
Houžvičková
E
E
Libertinová
J
J
Lišková
P
P
Mat'oška
V
V
Nyč
O
O
Mináriková
M
M
D057134:Antibodies, Neutralizing / Q000097:blood* / Q000276:immunology; D001379:Azathioprine / Q000627:therapeutic use*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016899:Interferon-beta / Q000276:immunology / Q000627:therapeutic use*; D008775:Methylprednisolone / Q000627:therapeutic use*; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000097:blood / Q000188:drug therapy / Q000276:immunology*
D057134:Antibodies, Neutralizing; D007166:Immunosuppressive Agents; D016899:Interferon-beta; D001379:Azathioprine; D008775:Methylprednisolone